All Posts By

courtney cruickshank

Treating the AD Patient During COVID-19

By Podcast

Atopic dermatitis is a relentless, recurring, unreasonable, often recalcitrant inflammatory skin disease that impacts millions of children and adults in the United States alone and requires a tailored treatment plan and ongoing follow up. Now add a global pandemic to the mix – awesome. Join podcast host Dr Adam Friedman and atopic dermatitis antagonist Dr. Peter Lio as they discuss practical approaches to managing atopic dermatitis in the era of COVID-19. Telemedicine, topicals, and tons of systemic talk!

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme Regeneron.
Upon completion of this podcast, learners should be able to:
  • Formulate AD treatment plans that may decrease susceptibility and spread of viral infections, including COVID-19
  • Identify new and emerging therapeutic considerations for managing atopic dermatitis during the current COVID-19 pandemic

Understanding and Changing Patient Behavior and Minimizing Risk of UV Damage

By Podcast

Episode 2 of a 2-Part Series: “Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior”

Why is is that we tend to do things we know are bad for us? Candy, alcohol, Tinder…the list goes on. What about not following practices that have a library of evidence supporting their use, like sunscreen and photo-protection? To better understand this conundrum JDD Podcast host Dr. Adam Friedman recruited mental health guru Dr. Sherry Pagoto, Professor in the Department of Allied Health Sciences at the University of Connecticut and Director of the UConn Center for mHealth and Social Media, to dive deep into human behavior and how this relates to medical compliance. Find a couch to lie down on as you digest the litany of psychosocial pearls Dr. Pagoto shares, rounded out by some evidenced based guidance on using social media to engage a broader audience. #dontmissthispodcast

A CME exam is available for this podcast.

This enduring continuing education activity is supported by an independent medical education grant provided by Johnson & Johnson Consumer Inc. Participants who earn a minimum, passing grade of 70% would be eligible to receive up to 0.5 credit hours AMA PRA Category 1™ and ANCC credit per podcast. A total of 1 hour for this two-part Sun Protection series.

Learning Objectives:

Upon completion of this enduring, internet-based series of ontinuing education activities,  participants should be able to:

  • Develop strategies leading to effective clinician-patient dialogues to better motivate patients to integrate regular use of sunscreens in their skin care regimen

Disclosures:

Adam Friedman, MD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speaker’s Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Sherry Pagoto, PhD – Consultant: Neutrogena/Johnson & Johnson.

The Science of Sun Protection

By Podcast

Episode 1 of a 2-Part Series: “Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior”

Photoprotection works, plain and simple. Yet all too often we must defend good science, dispel unfounded myths, and offer our first born children to get our patients to utilize sunscreen the right way when this behavior directly and primarily benefits them. Why is this and how do we airdrop knowledge in a meaningful way? In part one of this bonus two part podcast series dedicated to the science and psychology of sunscreen use, AAD Vice President Elect Neal Bhatia, MD joins host Adam Friedman, MD to slather on some practical approaches to communicating sunscreen science and real world use.

A CME exam is available for this podcast.

This enduring continuing education activity is supported by an independent medical education grant provided by Johnson & Johnson Consumer Inc. Participants who earn a minimum, passing grade of 70% would be eligible to receive up to 0.5 credit hours AMA PRA Category 1™ and ANCC credit per podcast. A total of 1 hour for this two-part Sun Protection series.

Learning Objectives:
Upon completion of this enduring, internet-based series of continuing education activities, participants should be able to:

  • Differentiate features, benefits and limits of chemical and physical sunblocking products
  • Discuss the role of product formulation, delivery vehicle and patient type when recommending sun protection strategies
  • Review multifunctional approaches to photoprotection including use of sunscreen-containing moisturizers and other skin care products
  • Develop strategies leading to effective clinician-patient dialogues to better motivate patients to integrate regular use of sunscreens in their skin care regimen

Disclosures:
Adam Friedman, MD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speaker’s Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Neal Bhatia, MD – Affiliations with Abbvie, Aclaris, Almirall, Biofrontera, BMS, BiopharmX, Dermira, Encore, EPI Health, Ferndale, Foamix, Galderma, Intraderm, ISDIN, J&J, LaRoche- Posay, Leo, Lilly, Mayne, Menlo, Novartis, Ortho, Pfizer, Pierre-Fabre, Regeneron, Sanofi, SkinFix, Soligenix, SunPharma, Vidac, and Vyome.

Support the (On)cause: A Practical Review of Supportive Oncodermatology

By Podcast

Cancer sucks, plain and simple. What is often overlooked is that the life saving/altering therapies often come with substantial baggage adding to this proclamation with skin, hair, and nail adverse events significantly impacting quality of life and even treatment course. Enter supportive oncodermatology, and along with it the mastermind behind this rapidly emerging field, Dr. Mario Lacouture, Professor and Director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Lacatoure joins podcast host Dr. Adam Friedman to discuss the array of cutaneous clusters that not only can, but are almost expected to occur during cancer therapy. Learn how even simple OTC products can contribute to both ameliorating and even preventing some of these sequelae. Understand how you (yeah, I’m talkin’ to you) can make an extraordinary impact in these patients’ lives. Tune in to this podcast to support your supportive oncoderm fund of knowledge.

This podcast was supported by Johnson & Johnson Consumer Inc.

Upcoming Related Supplement:

The Biological Impact of Oats: Eczema and Beyond
Blair Allais MD and Adam Friedman MD FAAD
Department of Dermatology, George Washington School of Medicine and Health Sciences, Washington, DC
October 2020 | Volume 19 | Issue 10 | Supplement| Copyright © October 2020

Best Practices & Pearls Safely Reopening Derm Practices

By Podcast

The COVID-19 pandemic has affected dermatology practices across the country and around the world. In the face of a change that no one was really prepared for, Dr. Jeffrey S. Dover, in partnership with the JDD, invited a panel of dermatology Key Opinion Leaders to share their experience via video as they reopen their practices. We have gathered the audio from all of these videos and assembled them into an easy to listen to podcast filled with practical pearls and best practices from Drs. Jeffrey Dover, Nazanin Saedi, Kavita Mariwalla, Terrence Keaney, and Thomas Rohrer.

This video series and podcast are supported in part by Alastin Skincare, Endo Aesthetics, Ortho Dermatologics, and Sciton.

We hope these pearls and best practices help with safely reopening your practice!

Watch the companion videos here:
https://jddonline.com/reopening-derm-practices

Read the full Project AesCert Guidance in the July eJDD here:

Systemic Antibiotics in the Management of Acne: Issues and Considerations for Optimal Care

By Podcast
WEEEEEEERE BACK! Join host Dr. Adam Friedman for lively and learned discussion with Dr. Joslyn Kirby on one of the most common, chronic, soul-crushing complaints… Acne Vulgaris. It is, from a pathophysiological standpoint, a biological sh*t show, but you need to understand it to develop the best treatment plans. We talk inflammation, first line approaches, setting patient expectations and compliance. We dive deep into the differences between broad-spectrum and narrow-spectrum antibiotics, when to use them, and for how long. (Spoiler alert: NOT TOO LONG!). In our efforts to be stewards of meaningful antibiotic use and adversaries of antimicrobial resistance, narrow-spectrum antibiotics are the future!
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Upon completion of this enduring, internet-based educational activity, participants should be able to:
  • Review current scientific understanding of pathophysiology of acne
  • Summarize acne treatment strategies utilizing systemic antibiotics
  • Differentiate safety and efficacy of broad and narrow spectrum antibiotics indicated for acne treatment
  • Cite the benefits of narrow spectrum antibiotic use in acne therapy
Disclosures:
Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speaker’s Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Joslyn R. Sciacca Kirby, MD – No relevant disclosures.

What Women DON’T Want… Psoriasis

By Podcast
In this edition of the JDD Podcast, Dr. Adam Friedman is joined by Dr. Deirdre Hooper, Associate Clinical Professor in the Department of Dermatology at both Louisiana State University and Tulane University, to discuss her article “Impact of Psoriasis on Women” in the September 2019 issue of the JDD on the unique considerations for the adult female psoriasis patient. What questions should you be asking? What matters most when discussing therapeutic options? What is the best way to partner to ensure a long term relationship? If we could read minds this podcast would not be necessary but alas, it sorely is. Check it out!
JDD Article Referenced in this Podcast:
Impact of Psoriasis on Women
Deirdre Hooper MD

Choosing Wisely: Capitalizing on Atopic Dermatitis Clinical Trial Data for Meaningful Selection of Topical Agents

By Podcast

We are finally getting what we asked for: Pharma is ponying up for head to head studies to provide us with meaningful data to help make better clinical decisions. However, these valuable projects are often with systemic agents, such as biologics, leaving topical treatments in the dust. To address this, Dr. Lawrence Eichenfield, Professor of Dermatology and Pediatrics, UCSD, and colleagues sought to make the most out of the data we do have on the litany of topical options for atopic dermatitis and provide efficacy and safety guidance (A for effort!). Tune in to hear what this dream team concocted about creams. Hear how an expert approaches new atopic dermatitis patients. Don’t miss out – this is all very topical.

JDD Article Referenced in this Podcast:
Topical Agents for the Treatment of Atopic Dermatitis
Lawrence F. Eichenfield MD, Thomas Luger MD, Kim Papp MD, Jonathan I. Silverberg MD PhD MPH, Debra Sierka PhD, Chuanbo Zang PhD, Anna M. Tallman PharmD, Michael A. Zielinski PharmD, William C. Ports DVM
J Drugs Dermatol. 2020;19(1):50-64. doi:10.36849/JDD.2020.4508
https://jddonline.com/articles/dermatology/S1545961620P0050X

A CME exam is available for this podcast.

Learning Objectives:
Upon completion of this enduring activity, participants should be able to:
discuss the efficacy and safety of different topicals indicated for topic dermatitis,
as well as unique approaches to managing this complex yet extremely common condition.

Disclosures:
Lawrence Eichenfield has been a consultant, investigator, data safety monitoring board member, or speaker for AbbVie, Allergan, Anacor, Arcutis, Dermavant, Dermira, Eli Lilly, Galderma, LEO Pharma, Medimetriks, Novartis, Otsuka, Pfizer Inc., Regeneron, Sanofi-Genzyme, OrthoDerm/Valeant, and UCB.

Adam Friedman has been a consultant and speaker for Regeneron, Sanofi-Aventis, Ortho Dermatologics, and Pfizer.

Tapping Tattoo Artists as a Unique Approach to Disseminating Photoprotection Education

By Podcast
Continued efforts by the dermatology community to educate the public on both photoprotective measures and early skin cancer detection through surveillance has made a significant impact but the battle is far from over, especially in diverse skin phototypes for whom myths and misinformation are still pervasive regarding this space. Innovative strategies are still sorely needed! Enter mentor-mentee duo Robert P. Dellavalle MD PhD MSPH from the University of Colorado School of Medicine and Cristian D. Gonzalez MD from University of Texas Southwestern, who are no doubt going to create some buzz with their December 2019 JDD study “Hispanic Tattoo Artists Could Provide Skin Cancer Prevention via Aftercare Instructions and Social Media.” Tune in to hear how both doctors and artists can become allies in canvas (aka skin) cancer education dissemination. Learn how social media can be used as an effective research tool to both recruit and collect data. By the time you are through with this custom work, you will be loyal to the coil.
JDD Article Referenced in this Podcast:
Hispanic Tattoo Artists Could Provide Skin Cancer Prevention via Aftercare Instructions and Social Media
Cristian D. Gonzalez MD, Adrian Pona MD, Barbara J. Walkosz PhD, Robert P. Dellavalle MD PhD MSPH
J Drugs Dermatol. 2019;18(12):1237-1243.
A CME exam is available for this podcast.
Learning Objectives:
Upon completion of this enduring activity, participants should be able to:
  • discuss gaps in Hispanic tattoo artists’ understanding of skin cancer and willingness to disseminate sun protection information
  • identify opportunities to improve sun safety practices in at risk populations
  • and utilize social media as an emerging population health research tool.
Disclosures:
Adam Friedman, MD – No disclosures.
Robert Dellavalle, MD – No disclosures.
Cristian Gonzalez, MD – No disclosures.

Picking on Pruritus as a Problematic Clinical Biomarker in Autoimmune Connective Tissue Diseases

By Podcast

Pruritus is the worst – plain and simple. However we have only just scratched the surface with respect to why it happens in a multitude of clinical scenarios and what it could be telling us other then “SCRATCH ME.” In this edition of the JDD Podcast, Dr. Gideon Smith, assistant professor of dermatology at Harvard Medical school, Vice Chair for Clinical Affairs in Dermatology, and Director of the Connective Tissue Diseases Clinic and Fellowship joins us to pick apart his recent study in the JDD October 2019 edition, Characterizing Pruritus in Autoimmune Connective Tissue Diseases. Tune in to learn how not all itch is created equal in the autoimmune connective tissue world. Determine what questions can help guide management and therapy selection. Hear how to connect with rheumatology to forge a long lasting partnership, just like itchy and scratchy.

 

JDD Article Referenced in this Podcast:
Yahya Argobi MD FAAD, Gideon P. Smith MD MPH PhD
J Drugs Dermatol. 2019;18(10):995-998.
A CME exam is available for this podcast.
Learning Objectives:
Upon completion of this enduring activity, participants should be able to:
  • discuss the frequency, location, severity, and timing relative to the onset of pruritus and cardiovascular diseases.
Disclosures:
Adam Friedman, MD – Menlo Therapeutics (Advisory Board)
Gideon Smith, MD MPH PhD – Menlo Therapeutics (Grant/Research Support)

Don’t Go Zero to TEN: Identifying Gaps that Lead to Drug Re-exposure in Toxic Epidermal Necrolysis

By Podcast

We’ve all been there – that dreaded middle of the night page/call from the ER. Three simple words that send us spinning: “Rule out TEN.” Have no fear though, because the skin sloughing savoir is here. Inpatient dermatology service director Dr. Helena Pasieka joins us to discuss her recent research that elucidates opportunities to prevent offending agent re-exposure (aka first time shame on you, second time shame on us) in patients with a history of SJS/TEN. Simple steps can be taken to improve communication and prevention. Even more importantly, Dr. Pasieka walks us through her tried and true approach to that r/o call, key findings to guide your decision making, and what to when. Listening to this podcast may save someone’s life…

JDD Article Referenced in this Podcast:
Recommendations for Prevention of Drug Re-Exposure in Toxic Epidermal Necrolysis
Kathleen F. O’Brien MS, Karl M. Saardi MD, Laura S. Johnson MD, Jeffrey W. Shupp MD, Nemanja Rodic MD PhD, and Helena B. Pasieka MD MS
J Drugs Dermatol. 2019;18(10):1049-1052.
https://jddonline.com/articles/dermatology/S1545961619P1049X

A CME exam is available for this podcast.

Learning Objectives:
Upon completion of this enduring activity, participants should be able to:
Discuss common reasons for SJS patient re-exposure to offending agents and
Review an orderly approach to diagnosing and managing SJS/TEN spectrum.

Disclosures:
Adam Friedman, MD – No relevant disclosures.
Helena Pasieka, MD – No relevant disclosures.

Picking up on Prescribing Patterns for Psoriasis: A Real Deal Assessment

By Podcast

We (and our patients) are fortunate to live during a time when we have many safe and effective options to treat a chronic inflammatory skin disease such as Psoriasis. We are reminded of this, nay inundated, with warm and fuzzy headlines in the lay dermatology press that humblebrag said efficacy. However, how does this translate to the real world, when the perfect, neat lines of clinical trials are blurred by practical issues such as access, patient and practitioner perception, and long term use and efficacy? In a JDD Podcast first, we had not one but two investigators share their work and first steps to evaluate just that. Dr. Megan Noe, Instructor of Dermatology at the Brigham and Women’s Hospital and Harvard Medical School, and Dr. Joel Gelfand, Professor of Dermatology and of Epidemiology, Vice Chair for Clinical Research (Dermatology), and Director of the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania join us to discuss their study Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Databasefrom the August 2019 edition of the JDD. Hear how they formulated this big data dive. Learn which biologics did not get an encore with a refill. Discover which scenarios most often lead our colleagues to use combination therapy and with what. And most importantly, digest Dr. Noe and Gelfands’ approach to picking the right biologic for the right patient. All that and more – I (nail) pity the fool who doesn’t check it out.

A CME exam is available for this podcast.
Learning Objectives:
Upon completion of this enduring activity, participants should be able to:
  • discuss prescribing  patterns associated with biologic therapies for psoriasis
  • and utilization of concomitant non-biologic psoriasis therapies in patients on biologics.
Disclosures:
Joel Gelfand, MD – Dr. Gelfand served as a consultant for BMS, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Boehringer Ingelheim, Janssen, Novartis Corp , Celgene, Ortho Dermatologics, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics and Novartis. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma. Dr Gelfand is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology.
Megan Noe, MD – No relevant disclosures.
Adam Friedman, MD – No relevant disclosures.